InnSight Technology

Executive Summary

InnSight Technology is a Seattle-based diagnostics and digital health company founded in 2016, focused on developing OcuCheck, a point-of-care biosensor for non-invasive, quantitative analysis of biomarkers in tear fluid. The device aims to enable rapid diagnosis and management of both ocular and systemic diseases, addressing a significant gap in accessible, non-invasive diagnostic tools. Its initial target applications include dry eye disease and diabetic retinopathy screening, leveraging the rich biomarker content of tears to provide real-time results without the need for blood draws or specialized lab equipment. The company's platform has the potential to expand into other chronic conditions, positioning it as a versatile tool in primary care and ophthalmology settings. Despite the promising technology, InnSight remains in an early stage, with no disclosed funding rounds or commercial products. The company faces significant technical and regulatory hurdles, including validation of tear biomarker correlations and achieving clinical sensitivity/specificity comparable to established methods. However, the growing demand for decentralized diagnostics and the increasing prevalence of diabetes and ocular disorders provide a favorable market tailwind. Success will depend on securing strategic partnerships and navigating FDA clearance pathways efficiently. Overall, InnSight offers a unique diagnostic approach that could disrupt traditional laboratory testing, though execution risk remains high.

Upcoming Catalysts (preview)

• Q1 2027Completion of clinical feasibility study for OcuCheck in dry eye disease60% success
• Q2 2027Series A funding round to support regulatory and manufacturing scale-up50% success
• Q4 2027Submission of FDA 510(k) premarket notification for OcuCheck30% success